Skip to main content
See every side of every news story
Published loading...Updated

Launch of Wegovy Pill Looks to Be Going Strong so Far

Summary by STAT
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we see a new synthetic biology startup, backed by Frances Arnold and Bob Langer. Plus, it’s still early, but Novo Nordisk already appears to be having a robust rollout of the Wegovy pill. New FDA pathway brings promise, and concerns Bioethicists including the University of Pennsylvania’s Holly Fernandez Lync…

5 Articles

Since their arrival on the market, the new drugs against obesity, similar to the GLP-1, shake the pharma industry. With their effects on satiety, and the promise of consequent weight loss, they have already brought several tens of billions of dollars to the two star laboratories on the market: the American company Lilly, which has become the most valued pharmaceutical laboratory in the world and the Danish giant Novo Nordisk.

Major bank: Wegovy pill could reach peak sales of over DKK 40 billion. Novo Nordisk has already increased its value by approximately 20 percent since the pill version of Wegovy was approved in the US before Christmas. The first prescription figures

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

BizToc broke the news in on Sunday, January 25, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal